Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-19T04:28:52.705Z Has data issue: false hasContentIssue false

HEALTH TECHNOLOGY ASSESSMENT

The Pharmaceutical Industry Perspective

Published online by Cambridge University Press:  21 May 2002

Francois Schubert
Affiliation:
Glaxo Wellcome Research and Development, United Kingdom

Abstract

Increasingly, health technology assessment (HTA) is used to aid decisions on the reimbursement of pharmaceuticals or recommendations for their use. The pharmaceutical industry seeks to work in partnership with HTA agencies; however, this presents a number of challenges. Clinical trials will need to include appropriate measures that capture economic and patient benefits as well as relevant clinical endpoints, and the industry will want to seek international harmonization of the many guidelines for economic evaluation. The problem of demonstrating cost-effectiveness of a product before it is available for use must be addressed, possibly by conditional reimbursement to allow collection of real world evidence. It is also important that reimbursement decision makers minimize bias, play fair, and adhere to the written rules they issue. If the industry fairly demonstrates the value of a product using the best available evidence, HTA agencies should be transparent in the rationale for their recommendations.

Type
Research Article
Copyright
© 2002 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)